Dimensional Fund Advisors LP Sells 342,131 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Dimensional Fund Advisors LP cut its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 11.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,560,103 shares of the company's stock after selling 342,131 shares during the period. Dimensional Fund Advisors LP owned about 1.17% of Hims & Hers Health worth $61,910,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Crewe Advisors LLC bought a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. increased its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $38,000. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HIMS shares. Needham & Company LLC upped their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Truist Financial dropped their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Morgan Stanley cut their price objective on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a report on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and an average target price of $36.92.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded up $1.12 during trading hours on Monday, hitting $41.94. The company had a trading volume of 71,382,429 shares, compared to its average volume of 17,023,135. Hims & Hers Health, Inc. has a one year low of $11.45 and a one year high of $72.98. The firm has a market cap of $9.32 billion, a PE ratio of 95.32 and a beta of 1.84. The firm has a 50-day moving average of $32.21 and a 200 day moving average of $31.56.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.09. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 50,000 shares of Hims & Hers Health stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $36.39, for a total value of $1,819,500.00. Following the completion of the transaction, the chief executive officer now directly owns 92,103 shares of the company's stock, valued at $3,351,628.17. The trade was a 35.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 662,081 shares of company stock valued at $26,241,044. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.